Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04241341 · ClinicalTrials.gov registry record · Phase 3
Does Immediate Lymphatic Reconstruction Decrease the Risk of Lymphedema After Axillary Lymph Node Dissection
A Phase 3 study of Breast Cancer Lymphedema, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 3
- Development phase
- 180
- Enrollment target
- 7
- Study locations
NCT04241341: Active Phase 3 study of Breast Cancer Lymphedema, sponsored by Memorial Sloan Kettering Cancer Center.
NCT04241341 is a Phase 3 study of Breast Cancer Lymphedema that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 180 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (77% lower). The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04241341, a Phase 3 study of Breast Cancer Lymphedema, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 180 participants
- Enrollment target
- 7
- Study locations
Study Summary
The researchers are doing this study to see if having immediate lymphatic reconstruction after axillary lymph node dissection (ALND) can decrease the development of lymphedema, a side effect of ALND. Other purposes of the study include: Comparing the approach of immediate lymphatic reconstruction after ALND with the approach of ALND alone Looking at whether having immediate lymphatic reconstruction after ALND improves a person's quality of life Seeing if adding standard of care radiation therapy to either study approach (immediate lymphatic reconstruction after ALND or ALND alone) has an effect on development of lymphedema
Primary Outcome
as measured by arm volume will be a ≥10% increase in arm volume
Conditions Studied
Interventions
- PROCEDURE Axillary Lymph Node Dissection with Immediate Lymphatic Reconstruction
- PROCEDURE Axillary Lymph Node Dissection without Immediate Lymphatic Reconstruction
- OTHER quality-of-life questionnaires
- OTHER measured by arm volume
Study Locations (7)
New York
- Memorial Sloan Kettering Commack (Consent only) - Commack
- Memorial Sloan Kettering Westchester (Consent Only) - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau (Consent only) - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge (Consent and Followup) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Consent Only) - Middletown
- Memorial Sloan Kettering Bergen (Consent Only) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2020-01-22 |
| Est. Completion | 2027-01 |
| Phase | Phase 3 |
What the registry record for NCT04241341 still lists
NCT04241341 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Breast Cancer Lymphedema appearing as the primary indexed condition, and to 4 interventions - of which Axillary Lymph Node Dissection with Immediate Lymphatic Reconstruction is the first listed.
NCT04241341 lists 7 locations in 2 states (New York, New Jersey).
Frequently Asked Questions
What is clinical trial NCT04241341 about?
NCT04241341 is a clinical study titled "Does Immediate Lymphatic Reconstruction Decrease the Risk of Lymphedema After Axillary Lymph Node Dissection". The researchers are doing this study to see if having immediate lymphatic reconstruction after axillary lymph node dissection (ALND) can decrease the development of lymphedema, a side effect of ALND. Other purposes of the study include: Comparing the approach of immediate lymphatic reconstruction a...
What is the current status of trial NCT04241341?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 180 participants. The study started on 2020-01-22. Estimated completion is 2027-01.
What conditions does trial NCT04241341 study?
This clinical trial studies the following conditions: Breast Cancer Lymphedema.
What interventions are being tested in trial NCT04241341?
The interventions under investigation include: Axillary Lymph Node Dissection with Immediate Lymphatic Reconstruction (PROCEDURE), Axillary Lymph Node Dissection without Immediate Lymphatic Reconstruction (PROCEDURE), quality-of-life questionnaires (OTHER), measured by arm volume (OTHER).
Who is sponsoring clinical trial NCT04241341?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04241341 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer Lymphedema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04241341's enrollment target sits among peer trials
180 1422nd of 2000 higher than 564 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI